194 related articles for article (PubMed ID: 16393434)
1. Assessment of Canadian provincial expenditures in depressed patients treated with venlafaxine XR versus SSRIs: the APEX Study.
Monfared AA; Han D; Sheehy O; Bexton B; Lelorier J
Curr Med Res Opin; 2006 Jan; 22(1):83-94. PubMed ID: 16393434
[TBL] [Abstract][Full Text] [Related]
2. Pharmacy and medical costs associated with switching between venlafaxine and SSRI antidepressant therapy for the treatment of major depressive disorder.
Khandker RK; Kruzikas DT; McLaughlin TP
J Manag Care Pharm; 2008 Jun; 14(5):426-41. PubMed ID: 18597572
[TBL] [Abstract][Full Text] [Related]
3. Medical resource use and cost of venlafaxine or tricyclic antidepressant therapy. Following selective serotonin reuptake inhibitor therapy for depression.
Griffiths RI; Sullivan EM; Frank RG; Strauss MJ; Herbert RJ; Clouse J; Goldman HH
Pharmacoeconomics; 1999 May; 15(5):495-505. PubMed ID: 10537966
[TBL] [Abstract][Full Text] [Related]
4. The pharmacoeconomics of venlafaxine in depression.
Morrow TJ
Am J Manag Care; 2001 Sep; 7(11 Suppl):S386-92. PubMed ID: 11570029
[TBL] [Abstract][Full Text] [Related]
5. One-year costs of second-line therapies for depression.
Sullivan EM; Griffiths RI; Frank RG; Strauss MJ; Herbert RJ; Clouse J; Goldman HH
J Clin Psychiatry; 2000 Apr; 61(4):290-8. PubMed ID: 10830151
[TBL] [Abstract][Full Text] [Related]
6. A multinational pharmacoeconomic evaluation of acute major depressive disorder (MDD): a comparison of cost-effectiveness between venlafaxine, SSRIs and TCAs.
Doyle JJ; Casciano J; Arikian S; Tarride JE; Gonzalez MA; Casciano R
Value Health; 2001; 4(1):16-31. PubMed ID: 11704969
[TBL] [Abstract][Full Text] [Related]
7. Healthcare expenditure in severely depressed patients treated with escitalopram, generic SSRIs or venlafaxine in the UK.
Wade AG; Saragoussi D; Despiégel N; François C; Guelfucci F; Toumi M
Curr Med Res Opin; 2010 May; 26(5):1161-70. PubMed ID: 20297951
[TBL] [Abstract][Full Text] [Related]
8. Treatment costs of venlafaxine and selective serotonin-reuptake inhibitors for depression and anxiety.
Wan GJ; Crown WH; Berndt ER; Finkelstein SN; Ling D
Manag Care Interface; 2002 Jun; 15(6):24-30. PubMed ID: 12087603
[TBL] [Abstract][Full Text] [Related]
9. Healthcare expenditure in patients treated with venlafaxine or selective serotonin reuptake inhibitors for depression and anxiety.
Wan GJ; Crown WH; Berndt ER; Finkelstein SN; Ling D
Int J Clin Pract; 2002; 56(6):434-9. PubMed ID: 12166541
[TBL] [Abstract][Full Text] [Related]
10. Higher costs and therapeutic factors associated with adherence to NCQA HEDIS antidepressant medication management measures: analysis of administrative claims.
Robinson RL; Long SR; Chang S; Able S; Baser O; Obenchain RL; Swindle RW
J Manag Care Pharm; 2006; 12(1):43-54. PubMed ID: 16420107
[TBL] [Abstract][Full Text] [Related]
11. Pharmacoeconomic analysis of venlafaxine in the treatment of major depressive disorder.
Einarson TR; Addis A; Iskedjian M
Pharmacoeconomics; 1997 Aug; 12(2 Pt 2):286-96. PubMed ID: 10170453
[TBL] [Abstract][Full Text] [Related]
12. Does the use of SSRIs reduce medical care utilization and expenditures?
Chung S
J Ment Health Policy Econ; 2005 Sep; 8(3):119-29. PubMed ID: 16278500
[TBL] [Abstract][Full Text] [Related]
13. Escitalopram in the treatment of major depressive disorder: clinical efficacy, tolerability and cost-effectiveness vs. venlafaxine extended-release formulation.
Llorca PM; Fernandez JL
Int J Clin Pract; 2007 Apr; 61(4):702-10. PubMed ID: 17394446
[TBL] [Abstract][Full Text] [Related]
14. A comparison of the direct costs and cost effectiveness of serotonin reuptake inhibitors and associated adverse drug reactions.
Sullivan PW; Valuck R; Saseen J; MacFall HM
CNS Drugs; 2004; 18(13):911-32. PubMed ID: 15521793
[TBL] [Abstract][Full Text] [Related]
15. Economic evaluation of duloxetine versus serotonin selective reuptake inhibitors and venlafaxine XR in treating major depressive disorder in Scotland.
Benedict A; Arellano J; De Cock E; Baird J
J Affect Disord; 2010 Jan; 120(1-3):94-104. PubMed ID: 19497623
[TBL] [Abstract][Full Text] [Related]
16. Remission from depression : a review of venlafaxine clinical and economic evidence.
Han D; Wang EC
Pharmacoeconomics; 2005; 23(6):567-81. PubMed ID: 15960553
[TBL] [Abstract][Full Text] [Related]
17. Venlafaxine extended release versus citalopram in patients with depression unresponsive to a selective serotonin reuptake inhibitor.
Lenox-Smith AJ; Jiang Q
Int Clin Psychopharmacol; 2008 May; 23(3):113-9. PubMed ID: 18408525
[TBL] [Abstract][Full Text] [Related]
18. A budget-impact and cost-effectiveness model for second-line treatment of major depression.
Malone DC
J Manag Care Pharm; 2007 Jul; 13(6 Suppl A):S8-18. PubMed ID: 17874482
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness of outpatient treatment in depressive patients with escitalopram in Germany.
Kulp W; von der Schulenburg JM; Greiner W
Eur J Health Econ; 2005 Dec; 6(4):317-21. PubMed ID: 16267659
[TBL] [Abstract][Full Text] [Related]
20. Cost effectiveness of duloxetine compared with venlafaxine-XR in the treatment of major depressive disorder.
van Baardewijk M; Vis PM; Einarson TR
Curr Med Res Opin; 2005 Aug; 21(8):1271-9. PubMed ID: 16083537
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]